Last reviewed · How we verify
AHES 25 minutes
AHES 25 minutes is a treatment for pigment disorders.
AHES 25 minutes is a treatment for pigment disorders. Used for Pigment disorders.
At a glance
| Generic name | AHES 25 minutes |
|---|---|
| Also known as | Ultracain D-S forte, Articaine hydrochloride 40 mg/ml + epinephrine 10 μg/ml |
| Sponsor | Netherlands Institute for Pigment Disorders |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
AHES 25 minutes works by addressing the underlying causes of pigment disorders, leading to improved skin tone and reduced symptoms.
Approved indications
- Pigment disorders
Common side effects
- Skin irritation
Key clinical trials
- Fractional Laser Assisted Topical Anesthesia (PHASE4)
- Fractional Laser Assisted Delivery of Anesthetics IIIb (PHASE4)
- Fractional Laser Assisted Delivery of Anesthetics (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AHES 25 minutes CI brief — competitive landscape report
- AHES 25 minutes updates RSS · CI watch RSS
- Netherlands Institute for Pigment Disorders portfolio CI